Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

M3 Wake Research, Inc

Neither a doctor nor a teaching hospital

Research payments

$2,449,060

1,323 payments

Through program year 2025, M3 Wake Research, Inc is reported as receiving $2,449,060 in research payments, across 1,323 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,832,027 719
2024 Research $181,113 325
2023 Research $136,709 204
2022 Research $72,737 45
2021 Research $34,978 11
2020 Research $137,289 8
2019 Research $54,207 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. Seqirus USA Inc $2,315,592 1,305 payments
  2. HemoSonics LLC $68,050 5 payments
  3. Becton, Dickinson and Company $33,050 1 payment
  4. Teva Pharmaceuticals USA, Inc. $24,268 10 payments
  5. Jazz Pharmaceuticals Inc. $8,100 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age $1,815,919 714 payments
  2. The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older $228,036 224 payments
  3. A Phase 2b, Randomized, Observer-Blind, Antigen and Adjuvant Dose-Confirmation Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine (aQIVc) in Older Adults =50 Years of Age $135,553 315 payments
  4. Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults $102,485 13 payments
  5. Evaluation of Whole Blood Samples from Subjects Taking Antithrombotic Medications on the Quantra $36,840 3 payments
  6. Veritor Antigen Assay $33,050 1 payment
  7. A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $24,268 10 payments
  8. Reference Range Pilot Study for the Quantra System Analyzer with the QStat Cartridge $23,583 1 payment
  9. Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults $18,841 35 payments
  10. A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age $14,758 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record